The role of ANXA2 in the non-classical release of hetero-oligomers containing S100A13, ProTα, and Syt-1 was demonstrated in a study performed via the intracellular delivery of anti-ANXA2 antibody into C6 glioma cells, as shown in Figure 3. Here, S100A13 is linked to central nervous system cancer.